Rebecca Soine, MD
Dermatology · Hammond, LANPI 1083874192
Payments from drug & device makers
What this record shows
The money is spread across several categories — food and beverage (56.0%), consulting fees and travel and lodging — rather than concentrated in one kind of arrangement. 32 manufacturers reported payments, led by Kyowa Kirin, Inc. at 48.0% of the total. Reporting peaked in 2019 at $5,414 and has fallen 72.9% since, to $1,470 in 2025.
Across 326 payments — averaging $35.82 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Kyowa Kirin, Inc.$6K
- AbbVie$1K
- Johnson & Johnson$517
- Galderma Laboratories, L.p.$426
- Lilly USA, LLC$355
- Sanofi$328
- plus $3K from 26 others
Across 27 payments — averaging $3034.13 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Sun Pharmaceutical Industries Inc.$77K
- Taro Pharmaceuticals USA, Inc.$5K
What the payments were for
- Consulting fees$4,00034%
- Travel & lodging$8297%
- Food & beverage$6,54156%
- Education$3073%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Kyowa Kirin, Inc. | 20 | $5,608 |
| AbbVie | 76 | $1,225 |
| Johnson & Johnson | 19 | $517 |
| Galderma Laboratories, L.p. | 22 | $426 |
| Lilly USA, LLC | 20 | $355 |
| Sanofi | 15 | $328 |
| Regeneron Healthcare Solutions, Inc. | 13 | $284 |
| E.r. Squibb & Sons, L.L.C. | 13 | $252 |
| Amgen | 12 | $250 |
| Pfizer | 13 | $233 |
| Journey Medical Corporation | 11 | $216 |
| Sun Pharmaceutical Industries Inc. | 10 | $190 |
| Helsinn Therapeutics (U.S.), Inc. | 12 | $184 |
| Almirall LLC | 7 | $180 |
| UCB, Inc. | 8 | $168 |
| Ortho Dermatologics, A Division Of Bausch Health US, LLC | 8 | $148 |
| Incyte Corporation | 7 | $140 |
| LEO Pharma Inc. | 7 | $122 |
| Janssen Scientific Affairs, LLC | 1 | $115 |
| Novartis | 5 | $112 |
| Mayne Pharma Commercial LLC | 5 | $103 |
| Sanofi-aventis U.S. LLC | 1 | $99 |
| Dermavant Sciences, Inc. | 4 | $85 |
| Revance Therapeutics, Inc. | 2 | $77 |
| Arcutis Biotherapeutics, Inc. | 3 | $48 |
| Boehringer Ingelheim | 2 | $45 |
| Botanix SB Inc | 2 | $38 |
| Medimetriks Pharmaceuticals, Inc. | 2 | $36 |
| Organon | 3 | $30 |
| Mallinckrodt Hospital Products Inc. | 1 | $27 |
| Organogenesis Inc. | 1 | $23 |
| Sensus Healthcare, Inc. | 1 | $12 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$11,677 in reported general payments places this provider in the 75th percentile of 189 dermatology providers in Louisiana.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| OtezlaApremilast | 20 | $106,031 |
| Taltz AutoinjectorIxekizumab | 11 | $78,505 |
| Dupixent PenDupilumab | 15 | $58,539 |
| Bexarotene | 17 | $13,465 |
| Pimecrolimus | 14 | $4,466 |
| Ketoconazole | 210 | $3,464 |
| Clobetasol Propionate | 75 | $2,942 |
| Fluorouracil | 44 | $2,731 |
| Tacrolimus | 23 | $2,362 |
| Triamcinolone Acetonide | 221 | $2,270 |
| Acitretin | 14 | $2,195 |
| Fluocinonide | 72 | $1,950 |
| Hydroxychloroquine Sulfate | 15 | $1,455 |
| Metronidazole | 23 | $1,019 |
| Hydrocortisone | 143 | $888 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| AmgenOtezla | $250 | $106,03120 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 75th percentile of 189 dermatology providers in Louisiana.
Other dermatology in Hammond
- Aimee CoscarartHammond$15K
- Haley HuntHammond$9K
- Katherine HolcombMetairie$411K
- William ClaiborneNew Orleans$374K
- Blair BuddenLafayette$329K
- Erin BohNew Orleans$277K
- Mara HaseltineNew Orleans$276K
- Sarah HaydelHouma$265K
- Frankie RholdonLafayette$227K
- William MassengalePrairieville$225K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.